The phagocytosis dysfunction in lupus nephritis is related to monocyte/macrophage CPT1a

•More circulating apoptotic cells is indicative of a failure in the clearance of dying cells in lupus.•Defects in the clearance/phagocytosis of apoptotic cells provokes the immune response to self-antigens.•Phagocytosis of apoptotic cells is modulated by monocyte/macrophage CPT1a expression.•Blood monocytes and macrophages isolated from kidneys have a reduced CPT1a and phagocytosis.•Macrophage therapy is effective only when macrophages in kidneys achieve a normal CPT1a expression. Macrophages must remove apoptotic cells to shield tissues from the deleterious components of dying cells. The development of chronic inflammation and autoimmune symptoms in systemic lupus is influenced by a deficiency in phagocytosis of apoptotic cells but the underlying mechanism is still unknown. Modifications in monocyte/macrophage phenotype brought on by an increase in their inflammatory phenotype would cause them to decrease the expression of CPT1a, which would reduce their ability to phagocytose, aggravating kidney damage in lupus nephritis. We aim to demonstrate that the deficiency of CPT1A in the immunological system determines lupus. For this purpose, we will monitor CPT1a expression in blood monocytes and phagocytosis and CPT1a expression of macrophages isolated from kidneys and the inflammatory state in kidneys in two experimental models of lupus nephritis such as lupus induced pristane model and in the OVA-IC in vivo model. Additionally, we will test if reestablishing CPT1a expression in tissue macrophages restores the lost phagocytic function. We evidenced that blood monocytes and macrophages isolated from kidneys in the two in vivo models have a reduced expression of CPT1a and a reduced phagocytosis. Phagocytosis could be restored only if macrophage administration leads to an increase in CPT1a expression in kidney macrophages. A new cell therapy to reduce kidney nephritis in lupus could be developed based on these results.